Limin Co., Ltd. announced that Inner Mongolia Xinweiyuan Biochemical Co., Ltd., a wholly-owned subsidiary of the company, obtained a filing notice for the synthetic biology R&D center and the intelligent manufacturing of synthetic biological products issued by the Inner Mongolia Dalat Development and Reform Commission. The project plans to invest 200 million yuan to mainly build a synthetic biology research and development center, an intelligent synthetic biological product manufacturing workshop and related auxiliary supporting facilities to produce ethyl polymycin and dinanping A biological products. After completion, it will produce 100 tons of ethyl polymycin biological products and 1 ton of dinanping A biological products per year after completion. The project still needs to complete administrative approvals such as EIA in the future.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.